Overview
Title
To require the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to publish a final rule relating to nonclinical testing methods.
ELI5 AI
H.R. 2821 is a plan to make a new rule that uses different ways to test things without using animals, making sure the rules fit with the latest science tricks.
Summary AI
H.R. 2821 is known as the “FDA Modernization Act 3.0.” This bill requires the Secretary of Health and Human Services to update regulations to include nonclinical testing methods, replacing any references to animal testing. The aim is to align with changes made by earlier legislation and ensure that new methods are part of the official rules. This includes modifying specific sections of the Code of Federal Regulations to reflect these updates, making the regulations consistent and up-to-date with current scientific practices.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
Summary of the Bill
The piece of legislation, titled the "FDA Modernization Act 3.0," introduced in the House of Representatives as H.R. 2821, mandates specific regulatory changes by the Secretary of Health and Human Services, through the Commissioner of Food and Drugs. The key focus is to update regulations concerning nonclinical testing methods. The bill requires that within a year of its enactment, references in certain sections of the Code of Federal Regulations pertaining to "animal" testing are to be replaced with "nonclinical" testing. The legislation also mandates an interim final rule to enforce these changes immediately and includes a technical amendment to adjust the numbering of subsections in the Federal Food, Drug, and Cosmetic Act.
Significant Issues in the Bill
One of the notable issues regarding this bill is the replacement of "animal" with "nonclinical" without providing a detailed definition of what constitutes a "nonclinical" test. This could result in ambiguity, leading to varied interpretations and potential inconsistencies in regulatory application. Another concern is the provision allowing the interim final rule to become effective without requiring a demonstration of "good cause." This bypass of procedural requirements could undermine the usual system of checks and balances and reduce transparency. Additionally, the broad language allowing amendments to any other section needed for regulatory consistency could lead to overreach or modifications that extend beyond the original intent of the legislation.
Impact on the Public
The bill might positively influence public perception by potentially reducing reliance on animal testing, aligning with ethical considerations and growing public concern over animal welfare. Enhancing nonclinical testing methods could also foster technological innovation and more humane scientific practices. However, the vagueness of the term "nonclinical" might raise confusion and concern regarding the reliability and validation of these new methods for ensuring public safety and drug efficacy.
Impact on Specific Stakeholders
For the pharmaceutical and biotechnology industries, the shift away from traditional animal testing could translate into significant changes in research and development protocol, possibly leading to increased efficiency and potentially lower costs in the long run. Nevertheless, there is a risk of initial uncertainty and disruption as industries adjust to new regulatory frameworks.
Regulatory bodies and laboratories might face challenges in interpreting and implementing the new requirements, particularly if clarity is lacking. They might need to invest in understanding and developing new testing methods that fit within the nonclinical framework.
Animal rights organizations could view this legislation positively, seeing it as a step towards reducing the ethical implications of animal testing. However, without a clear alternative framework, these groups might remain cautious about the effectiveness of the transition toward nonclinical methodologies.
Overall, the success of this bill in achieving its intended reforms will largely depend on how the new "nonclinical" standards are defined, implemented, and monitored, balancing scientific advancement with ethical practices.
Issues
The modification of regulatory language by replacing 'animal' with 'nonclinical' in Section 2(a)(1)(A) could introduce ambiguity or lead to inconsistent interpretations unless 'nonclinical' is clearly defined and universally understood across all regulatory frameworks.
The provision in Section 2(a)(3) allowing the interim final rule to take immediate effect without demonstrating 'good cause' might undermine procedural safeguards, potentially reducing transparency and oversight in regulatory changes.
In Section 2(b), the technical amendment involving the re-designation of subsections might lead to confusion if not properly communicated to stakeholders familiar with the original categorization, particularly those involved in clinical trial diversity action plans.
The broad allowance for amendments in any other section deemed necessary for regulatory consistency (Section 2(a)(2)(V)) can be perceived as overreaching or lacking specificity, which could lead to regulatory changes beyond what is necessary or intended.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The short title of this legislation is the “FDA Modernization Act 3.0.”
2. Regulations on nonclinical testing methods Read Opens in new tab
Summary AI
The section requires the Secretary of Health and Human Services to update regulations to replace references to "animal" testing with "nonclinical" testing in various parts of the Code of Federal Regulations and defines what a "nonclinical test" is. Additionally, it mandates an interim final rule that becomes effective immediately to ensure regulatory consistency with recent legislative changes, and makes a technical amendment to renumber a section of the Federal Food, Drug, and Cosmetic Act.